Search Results

Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage pharmaceutical company leading the way in therapies for inner ear disorders, today announced a strategic partnership with the Vestibular Disorders Association (VeDA).

Spiral Therapeutics, Inc., a clinical-stage company focused on delivering therapies for inner ear disorders, announced a new round of financing led by Esperante Ventures and Ferring Ventures SA.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition of selected assets from Otonomy, Inc.

Sequel, a startup, dedicated to engineering better health and wellness experiences for women, today announced that its breakthrough spiral tampon has received approval from the United States Food and Drug Administration (FDA) as a medical device.

Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company focused on delivering therapies for inner ear disorders, today announced that the Company recently completed an $8.25M financing, with new proceeds that will fund the continuing development of its lead candidate, SPT-2101, for the treatment of inner ear inflammation.

Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.

Initiates Development of Tailored Innovative Targeted Therapy for Refractory Cancer ReCerise Therapeutics Inc., has announced its selection for a grant from the Ministry of Trade, Industry and Energy of South Korea.